Roivant's eye drug clears two pivotal trials

Roivant and its partner Priovant said Wednesday that their drug worked in two separate trials. The drug is called brepocitinib. It treats a rare eye disease called non-infectious uveitis. Patients taking it did better than patients on a placebo, meeting both trials' main goal. Priovant plans to ask the FDA to approve it in the first half of 2027.

Uveitis doesn't get the same attention as cancer or diabetes, but repeated flares can permanently damage a patient's eyesight. Doctors mostly manage it with steroids today, which carry their own long-term risks. One caveat: these results come from the companies' own announcement. They haven't been published or checked by outside scientists yet.

Keep reading — what to watch

Will the data hold up once outside scientists see it? Topline results like these sometimes look different once the full numbers are published. If brepocitinib's results stand, Priovant's 2027 filing timeline looks realistic. A disease with no dedicated drug would finally get one built specifically for it.